The metabolic fate of [14C]clenbuterol was studied in male and female Wistar rats. After a single oral dose of 200 microgram/kg [14C]clenbuterol, in an 8-day study period, approximately 60% of the radioactivity was eliminated in urine; 20 and 30% of the radioactivity was excreted in feces by male and female rats, respectively. HPLC coupled to on-line radioactivity detection allowed the separation and quantitation of clenbuterol metabolites, some of which were found to be poorly stable in urine. Most of the urinary and fecal metabolites of clenbuterol were isolated and identified using various MS techniques. Analytical methods were also developed to establish the metabolic profiles in feces and tissues, up to 72 hr after clenbuterol administration. Clenbuterol was mainly metabolized by N-dealkylation (secondary amine), as well as N-oxidation and sulfate conjugation (primary amine). Gender-related differences in the rates of clenbuterol N-dealkylation were observed. 4-N-Hydroxylamine was the major metabolite detected in urine, whereas more than one half of the radioactivity in feces was associated with clenbuterol sulfamate.
Download full-text PDF |
Source |
---|
Hum Vaccin Immunother
December 2025
National Influenza Centre, Edificio Rondilla, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
Influenza accounts for 30% of the total morbidity and mortality in the European Union. However, the specific burden in different European countries is largely unknown, and more research is needed to ascertain the reality of this disease. In this retrospective study, we analyzed the burdens of hospitalization, intensive care unit (ICU) admission and in-hospital mortality in Spain over five seasons (2015-2020) via publicly available Minimum Basic Datasets (MDBS).
View Article and Find Full Text PDFJMIR Aging
January 2025
Centre of Expertise in Care Innovation, Department of PXL - Healthcare, PXL University of Applied Sciences and Arts, Hasselt, Belgium.
Background: Advancements in mobile technology have paved the way for innovative interventions aimed at promoting physical activity (PA).
Objective: The main objective of this feasibility study was to assess the feasibility, usability, and acceptability of the More In Action (MIA) app, designed to promote PA among older adults. MIA offers 7 features: personalized tips, PA literacy, guided peer workouts, a community calendar, a personal activity diary, a progression monitor, and a chatbot.
J Med Internet Res
January 2025
Department of Epidemiology, Boston University School of Public Health, Boston University, Boston, MA, United States.
Background: Digital gaming has become increasingly popular among older adults, potentially offering cognitive, social, and physical benefits. However, its broader impact on health and well-being, particularly in real-world settings, remains unclear.
Objective: This study aimed to evaluate the multidimensional effects of digital gaming on health and well-being among older adults, using data from the Japan Gerontological Evaluation Study conducted in Matsudo City, Chiba, Japan.
JMIR Res Protoc
January 2025
McMaster University, Hamilton, ON, Canada.
Background: Research has shown that engaging in a range of healthy lifestyles or behavioral factors can help reduce the risk of developing dementia. Improved knowledge of modifiable risk factors for dementia may help engage people to reduce their risk, with beneficial impacts on individual and public health. Moreover, many guidelines emphasize the importance of providing education and web-based resources for dementia prevention.
View Article and Find Full Text PDFJMIR Ment Health
January 2025
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.
Background: Evidence-based digital therapeutics represent a new treatment modality in mental health, potentially providing cost-efficient, accessible means of augmenting existing treatments for chronic mental illnesses. CT-155/BI 3972080 is a prescription digital therapeutic under development as an adjunct to standard of care treatments for patients 18 years of age and older with experiential negative symptoms (ENS) of schizophrenia. Individual components of CT-155/BI 3972080 are designed based on the underlying principles of face-to-face treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!